BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 35362798)

  • 21. Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Vélayoudom-Céphise FL; Duvillard P; Foucan L; Hadoux J; Chougnet CN; Leboulleux S; Malka D; Guigay J; Goere D; Debaere T; Caramella C; Schlumberger M; Planchard D; Elias D; Ducreux M; Scoazec JY; Baudin E
    Endocr Relat Cancer; 2013 Oct; 20(5):649-57. PubMed ID: 23845449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.
    Grundmann N; Voigtländer S; Hakimhashemi A; Pape UF; Meyer M; Müller-Nordhorn J
    Cancer Med; 2023 Oct; 12(19):19949-19958. PubMed ID: 37737059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
    Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
    Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
    World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know.
    Couvelard A; Cazes A; Cros J
    Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101795. PubMed ID: 37429760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
    Klöppel G
    Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms.
    Taboada R; Claro L; Felismino T; de Jesus VH; Barros M; Riechelmann RP
    J Neuroendocrinol; 2022 Apr; 34(4):e13099. PubMed ID: 35174558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3).
    Sorbye H; Baudin E; Borbath I; Caplin M; Chen J; Cwikla JB; Frilling A; Grossman A; Kaltsas G; Scarpa A; Welin S; Garcia-Carbonero R;
    Neuroendocrinology; 2019; 108(1):54-62. PubMed ID: 30153658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Sorbye H; Elvebakken H; Perren A; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Vestermark LW; Ladekarl M; Tabaksblat EM; Knappskog S
    Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37410378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
    Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?
    Borbon LC; Tran CG; Sherman SK; Ear PH; Chandrasekharan C; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2022 Oct; 29(11):6936-6946. PubMed ID: 35802214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors.
    Pasaoglu E; Dursun N; Ozyalvacli G; Hacihasanoglu E; Behzatoglu K; Calay O
    Ann Diagn Pathol; 2015 Apr; 19(2):81-7. PubMed ID: 25702616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
    Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.
    Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H
    Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Digital image analysis of Ki67 hotspot detection and index counting in gastroenteropancreatic neuroendocrine neoplasms.
    Saetiew K; Angkathunyakul N; Hunnangkul S; Pongpaibul A
    Ann Diagn Pathol; 2024 Aug; 71():152295. PubMed ID: 38547761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
    Ooki A; Osumi H; Fukuda K; Yamaguchi K
    Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
    Sorbye H; Kong G; Grozinsky-Glasberg S
    Endocr Relat Cancer; 2020 Mar; 27(3):R67-R77. PubMed ID: 31846429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.
    Merola E; Falconi M; Rinke A; Staettner S; Krendl F; Partelli S; Andreasi V; Gress TM; Pascher A; Arsenic R; Doglioni C; Kaemmerer D; Wiedenmann B; Pavel ME
    Am J Surg; 2020 Aug; 220(2):284-289. PubMed ID: 32209239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.